IMS 2022 | The role of daratumumab in the treatment of myeloma and insights into the MAIA trial
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, shares some insights into the role of daratumumab in the treatment of multiple myeloma, highlighting findings from the MAIA trial (NCT02252172). Dr Usmani first discusses the impact of daratumumab on the depth of response, overall survival (OS) and progression-free survival (PFS) in patients enrolled in this trial, and then goes on to comment on the importance of further improving treatment approaches for those with high-risk disease. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
